Primary Resistance in HIV Patients in Colombia

CompletedOBSERVATIONAL
Enrollment

527

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

April 1, 2024

Conditions
HIV Infection
Interventions
DIAGNOSTIC_TEST

HIV-1 plasma RNA Genotyping secuencing by Sanger technique

After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.

DIAGNOSTIC_TEST

HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique

After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.

Trial Locations (1)

760043

REVIVA, Red de VIH del Valle del Cauca, Santiago de Cali

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

collaborator

Centro de Investigación en. Enfermedades Infecciosas, Mexico

OTHER_GOV

lead

Fundacion REVIVA, Red de VIH del Valle del Cauca

NETWORK

NCT03957369 - Primary Resistance in HIV Patients in Colombia | Biotech Hunter | Biotech Hunter